Clinical Trials Directory

We are doing this study to compare 2 different regimens for treating pancreatic cancer after surgery. We what find out how well patients do after they get a combination of the drugs cevumeran, atezolizumab, and mFOLFIRINOX compared to just getting mFOLFIRINOX alone. Cevumeran is an experimental drug that is made from your own cells that are obtained from blood and tissue samples. It is designed to activate your immune system against cancer cells in your body.

We are doing this study to find out if a program called AYA STEPS has a positive benefit for young people who are treated for cancer. We want to know how well this program can help cancer survivors younger than 40 manage any physical or emotional symptoms they have after treatment, and we also want to see if the program can help them be more engaged with follow-up care.

If you qualify for the study, a computer will choose your medicine by chance. This means you could get AZD0780 or a pill that does not have medicine, called a placebo. It is like flipping a coin, so you have a 1 in 2 chance of getting AZD0780. Neither you nor your doctor will know which one you get. You will take one pill by mouth every day. Each pill is 30 milligrams. You will visit the study site up to 15 times. These visits will happen at the start and then at different weeks, like week 0, 2, 4, 12, and so on. Each visit will take about 1 to 2 hours. Your doctor will tell you what tests and steps you need to do. Before each visit, you cannot eat or drink anything except water for at least 8 hours. You can drink water during this time.

This study includes a screening visit, a treatment period lasting 8 to 12 weeks, and a follow-up. During the screening, you will have a medical exam, and information about your health and background will be collected from your hospital records. If you qualify and choose to join, you will take Vitamin B6 once a day for 8 to 12 weeks. You and a caregiver will receive study questionnaires electronically. These will be sent within 7 days after you join the study, before you start taking Vitamin B6, and again after your follow-up visit. You will have up to 14 days to complete each set of questionnaires. There is no special visit at the end of treatment. The study ends once you finish the final set of questionnaires after taking Vitamin B6.

We are doing this study to test different drugs to see if they are safe and helpful for adults who are admitted in the hospital with acute respiratory distress syndrome (ARDS) compared to placebo (a substance that looks like a drug but does not contain an active drug).

We are doing this study to compare the outcomes of 2 treatments for women with stress urinary incontinence (SUI): transurethral bulking agent (TBA) and single-incision sling (SIS). Both treatments are FDA-approved and can help improve SUI symptoms, but they have not been directly compared to each other to see which treatment is better for certain patients and under what circumstances. We hope this study can help women and their doctors find out which option is most likely to have the best results. Current evidence suggests that TBA and SIS are less effective than a traditional full-length mid-urethral sling procedure, but both options are less invasive and less likely to cause complications afterward.

We are doing this study to find out whether certain immunotherapy drug combinations with and without chemotherapy given before and after surgery for mesothelioma can help prevent the tumor from coming back. The two immunotherapy drugs, durvalumab and tremelimumab, are called immune checkpoint inhibitors and are used to activate the immune system against cancer. Immune checkpoint inhibitors are now approved for mesothelioma for patients who cannot undergo surgery, but they are not approved prior to surgery. The chemotherapy drugs (cisplatin or carboplatin and pemetrexed) are standard options for the treatment of mesothelioma.

We are doing this study to find out if an investigational drug called TP-3654 (the study drug) is a safe and effective treatment for myelofibrosis. The study drug will be tested at different doses to find out what effects, if any, it has on myelofibrosis.